cystic fibrosis

Messenger RNA
Biotech

Arcturus doubles down on mRNA, axes several early-stage assets

Analysts said the discontinued programs—mRNA vaccines for chlamydia, gonorrhea and Lyme disease—had “low [return on investment] visibility.”
Ben Adams , Gabrielle Masson May 13, 2025 1:32pm
pause button on blue background

Vertex takes $379M hit tied to cancelled islet cell program

May 6, 2025 12:50pm
Photo of Wall Street street sign with american flags in the background

Sionna goes public in $135M IPO, Aardvark plots $103M listing

Feb 7, 2025 4:40am
IPO initial public offering

Sionna eyes up $156M IPO to fund cystic fibrosis trials

Feb 3, 2025 9:59am
IPO initial public offering Wall Street

Odyssey, Sionna join band of biotechs braving the IPO waters

Jan 21, 2025 5:27am
x ray cystic fibrosis

Sionna salvages AbbVie assets for assault on cystic fibrosis

Jul 16, 2024 10:00am